## CHRW: C.H. Robinson Worldwide, Inc. - XLI: Industrials

### Executive Summary

No thesis match: MRS_10 -1.4% below STRENGTH zone (3.0-6.0%); PEG 2.32 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.1% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($155.48)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Neutral (Bullish: 0, Bearish: 1)

**1. C.H. Robinson Surges 71.6% in 6 Months: What Should Investors Do Now?**
- Source: TradingView â€” Track All Markets | 20251229T190744 | Neutral | Relevance: 100%
- C.H. Robinson Worldwide, Inc. (CHRW) stock has seen a significant 71.6% surge over the last six months, outperforming its industry peers. This performance is attributed to consistent dividend payments, share buybacks, and decreased operating expenses. However, headwinds such as weak freight demand and a concerning liquidity position currently make it a "Hold" according to Zacks Rank, suggesting investors already holding the stock should retain it, but new investors wait for a better entry point.

**2. Marathon Asset Management Ltd Sells 36,620 Shares of C.H. Robinson Worldwide, Inc. $CHRW**
- Source: MarketBeat | 20251229T113209 | Neutral | Relevance: 100%
- Marathon Asset Management Ltd reduced its stake in C.H. Robinson Worldwide, Inc. by 26.3% in the third quarter, selling 36,620 shares. This comes amidst significant insider selling from Angela K. Freeman and Michael D. Castagnetto in November. Despite these sales, analysts generally maintain a "Moderate Buy" consensus rating with an average price target of $149.48, and the company recently increased its quarterly dividend.

**3. C.H. Robinson Surges 71.6% in 6 Months: What Should Investors Do Now?**
- Source: Finviz | 20251229T200739 | Neutral | Relevance: 100%
- C.H. Robinson Worldwide, Inc. (CHRW) has seen a significant 71.6% surge in its stock over the last six months, outperforming its industry and competitors. Despite this impressive rally and CHRW's consistent shareholder-friendly initiatives and attractive valuation, investors are advised against buying due to weak freight demand and a concerning liquidity position. Current shareholders are encouraged to retain their investment, as the company holds a Zacks Rank #3 (Hold).

**4. Valley National Advisers Inc. Buys 15,962 Shares of C.H. Robinson Worldwide, Inc. $CHRW**
- Source: MarketBeat | 20251228T125600 | Somewhat-Bullish | Relevance: 100%
- Valley National Advisers Inc. significantly increased its stake in C.H. Robinson Worldwide, Inc. (NASDAQ:CHRW) by 106,413.3%, acquiring an additional 15,962 shares during the third quarter, bringing their total holdings to 15,977 shares valued at approximately $2.114 million. This move comes despite recent large insider sales from Angela K. Freeman and Michael D. Castagnetto, who sold shares totaling around $14.3 million. Analysts currently rate CHRW as a "Moderate Buy" with a consensus price target of $149.48, and the company recently reported beating EPS estimates, although revenue declined.

**5. 1 Cash-Producing Stock with Promising Prospects and 2 Facing Headwinds**
- Source: Finviz | 20251228T233700 | Bearish | Relevance: 84%
- This article identifies one industrial stock, KBR, with promising prospects due to rising operating profits, efficient spending, and improving returns on capital, alongside two cash-producing stocks, Fastenal (FAST) and C.H. Robinson Worldwide (CHRW), that are facing significant headwinds. Fastenal is experiencing slower revenue growth and declining free cash flow margins, while C.H. Robinson is impacted by declining revenue, high input costs, and waning returns on capital. The author recommends KBR as a stock to watch and suggests caution with FAST and CHRW.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-24 | B of A Securiti | $182 | $167 | +9% |
| 2025-12-16 | Stifel | $184 | $155 | +19% |
| 2025-12-16 | Barclays | $200 | $145 | +38% |
| 2025-12-08 | Morgan Stanley | $85 | $77 | +10% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-24 | B of A Securiti | main | Buy |
| 2025-12-16 | Stifel | main | Buy |
| 2025-12-16 | Barclays | up | Overweight |
| 2025-12-08 | Morgan Stanley | main | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 2 ($1.79M) |
| Sells | 2 ($0.38M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 54.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 12.0% (-3.0%)
- First Eagle Investme: 8.9% (-0.2%)
- Blackrock Inc.: 8.2% (-8.5%)
- Wellington Managemen: 6.1% (+198.6%)
- State Street Corpora: 5.8% (-7.4%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-2.1% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +19%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.32 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 34%). Analyst sentiment positive (4 raises, avg +19%). Insider buying signal ($1.8M), management confidence. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.1B |
| Beta | 0.91 |
| 52W Range | $84.68 - $167.90 |
| Short Interest | 6.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.32 |
| Forward P/E | 27.0 |
| Current P/E | 32.4 |
| YoY Growth | 20.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 0.7% to -1.4% (-2.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.4pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 58. OFD pattern: -FTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.40% (CS: 21) | Neutral |
| RSI_14 | 57.5 | Neutral |
| MACD Histogram | -0.30 | Bearish |
| vs SMA20 | 1.009x | Above |
| vs SMA50 | 1.065x | Above |
| vs SMA200 | 1.366x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $161.96
- **Stop Loss:** $155.48 (4.0% risk)
- **Target:** $168.44 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 203
- **Position Value:** $32,877.88
- **Portfolio %:** 32.88%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-01-28 (Est: $1.13)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.30 | $1.40 | +7.4% |
| 2025Q2 | $1.16 | $1.29 | +11.6% |
| 2025Q1 | $1.05 | $1.17 | +11.4% |
| 2024Q4 | $1.11 | $1.21 | +9.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*